Rheumatoid arthritis Musculoskeletal Diseases Rheumatoid arthritis
Conditions
Interventions
Sulphasalazine will be used as a disease modifying agent for 6 months, target dose 40 mg/kg (to maximum tolerated dose or 4 g daily as maximum permitted dose). At 6 months those with a suboptimal res
Sponsors
Arthritis Research Campaign (ARC) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female 2. Age 18 - 75 years 3. Onset of disease after age 16 4. Disease duration less than 5 years 5. Active inflammatory arthritis which is defined as six or more swollen joints plus two of the following: 5.1. Morning stiffness more than 45 minutes 5.2. Nine or more tender joints 5.3. Erythrocyte Sedimentation Rate (ESR) more than 28 mm/h
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed